• breast cancer - HER2-positive
• es-BC - HER2 negative - (neo)adjuvant (NA) 1
• es-BC - HER2 positive - (neo)adjuvant (NA) 4
• la/mBC - HER2 positive
• la/mBC - HER2 positive - (neo)adjuvant (NA)
• la/mBC - HER2 positive - 1st Line (L1) 5
• la/mBC - HER2 positive - 2nd Line (L2) 13

 

• antibody–drug conjugate
• trastuzumab emtansine
• trastuzumab emtasine plus endocrine therapy
• HER inhibitor
• HER2 inhibitor
• trastuzumab based treatment
• trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
• TKI anti HER1/EGFR and HER2/neu
• lapatinib based treatment
• lapatinib
• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone

• versus all
• vs HER inhibitor
• vs HER2 inhibitor
• vs trastuzumab based treatment
• vs trastuzumab
• vs trastuzumab plus endocrine therapy
• vs TKI anti HER1/EGFR and HER2/neu
• vs lapatinib based treatment
• vs lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)